NCT05076513 2026-03-09
Trial of Niraparib in Participants With Newly-diagnosed Glioblastoma and Recurrent Glioma
St. Joseph's Hospital and Medical Center, Phoenix
Phase EARLY_PHASE1 Active not recruiting
Clinical Trials
12 trialsNCT05406700 2026-02-09
Niraparib In Recurrent IDH 1/2 Gliomas
Massachusetts General Hospital
Phase EARLY_PHASE1 Active not recruiting
NCT05700721 2026-02-05
Phase II Trial of the PARP Inhibitor Niraparib and PD-1 Inhibitor Dostarlimab in Patients With Advanced Cancers With Active Progressing Brain Metastases (STARLET)
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT06388733 2026-02-03
A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Glioblastoma
NeuroTrials, LLC
Phase 3 Recruiting
NCT04992013 2026-01-23
Niraparib in Tumors Metastatic to the CNS
Massachusetts General Hospital
Phase 2 Active not recruiting
NCT04544995 2026-01-21
Dose Escalation and Cohort Expansion Study of Niraparib and Dostarlimab in Paediatric Participants With Solid Tumors (SCOOP)
GlaxoSmithKline
Phase 1 Terminated
NCT04221503 2026-01-08
Niraparib/TTFields in GBM
Abramson Cancer Center at Penn Medicine
Phase 2 Active not recruiting
NCT05297864 2025-05-23
OU-SCC-PI-4G
University of Oklahoma
Phase 2 Terminated
NCT06258018 2024-08-30
ONC-2022-001
Istituto Clinico Humanitas
Phase 1/2 Not yet recruiting
NCT05666349 2024-03-26
RiNG
University College, London
Phase 1 Withdrawn
NCT04715620 2021-01-20
Niraparib Combined With Radiotherapy in rGBM
Tianjin Huanhu Hospital
Phase 2 Unknown
NCT01294735 2012-08-15
Study of the Safety and Efficacy of MK-4827 Given With Temozolomide in Participants With Advanced Cancer (MK-4827-014 AM1)
Merck Sharp & Dohme LLC
Phase 1 Completed